Roth Capital Downgrades Recro Pharma (REPH) to Neutral, Will Await NT Strategy Disclosure
Tweet Send to a Friend
Roth Capital analyst Scott Henry downgraded Recro Pharma (NASDAQ: REPH) from Buy to Neutral with a price target of $7.50 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
